Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Conceptualizing syntactic categories as semantic categories: Unifying part-of-speech identification and semantics using co-occurrence vector averaging.

Westbury C, Hollis G.

Behav Res Methods. 2018 Sep 13. doi: 10.3758/s13428-018-1118-4. [Epub ahead of print]

PMID:
30215164
2.

The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.

Stubbs MC, Burn TC, Sparks RB, Maduskuie T, Diamond S, Rupar M, Wen X, Volgina A, Zolotarjova N, Waeltz P, Favata M, Jalluri R, Liu H, Liu XM, Li J, Collins R, Falahatpisheh N, Polam P, DiMatteo D, Feldman P, Dostalik V, Thekkat P, Gardiner C, He X, Li Y, Covington M, Wynn R, Ruggeri B, Yeleswaram S, Xue C, Yao W, Combs AP, Huber R, Hollis G, Scherle P, Liu P.

Clin Cancer Res. 2018 Sep 11. pii: clincanres.0098.2018. doi: 10.1158/1078-0432.CCR-18-0098. [Epub ahead of print]

PMID:
30206163
3.

Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.

Koblish H, Li YL, Shin N, Hall L, Wang Q, Wang K, Covington M, Marando C, Bowman K, Boer J, Burke K, Wynn R, Margulis A, Reuther GW, Lambert QT, Dostalik Roman V, Zhang K, Feng H, Xue CB, Diamond S, Hollis G, Yeleswaram S, Yao W, Huber R, Vaddi K, Scherle P.

PLoS One. 2018 Jun 21;13(6):e0199108. doi: 10.1371/journal.pone.0199108. eCollection 2018.

4.

When is best-worst best? A comparison of best-worst scaling, numeric estimation, and rating scales for collection of semantic norms.

Hollis G, Westbury C.

Behav Res Methods. 2018 Feb;50(1):115-133. doi: 10.3758/s13428-017-1009-0.

PMID:
29322399
5.

INCB040093 Is a Novel PI3Kδ Inhibitor for the Treatment of B Cell Lymphoid Malignancies.

Shin N, Li YL, Mei S, Wang KH, Hall L, Katiyar K, Wang Q, Yang G, Rumberger B, Leffet L, He X, Rupar M, Bowman K, Favata M, Li J, Liu M, Li Y, Covington M, Koblish H, Soloviev M, Shuey D, Burn T, Diamond S, Fridman J, Combs A, Yao W, Yeleswaram S, Hollis G, Vaddi K, Huber R, Newton R, Scherle P.

J Pharmacol Exp Ther. 2018 Jan;364(1):120-130. doi: 10.1124/jpet.117.244947. Epub 2017 Nov 10.

PMID:
29127109
6.

Estimating the average need of semantic knowledge from distributional semantic models.

Hollis G.

Mem Cognit. 2017 Nov;45(8):1350-1370. doi: 10.3758/s13421-017-0732-1.

PMID:
28707176
7.

Scoring best-worst data in unbalanced many-item designs, with applications to crowdsourcing semantic judgments.

Hollis G.

Behav Res Methods. 2018 Apr;50(2):711-729. doi: 10.3758/s13428-017-0898-2.

PMID:
28550657
8.

Effects of a hospital-wide intervention on emergency department crowding and quality: A prospective study.

Richardson DB, Brockman K, Abigail A, Hollis GJ.

Emerg Med Australas. 2017 Aug;29(4):415-420. doi: 10.1111/1742-6723.12771. Epub 2017 Apr 5.

PMID:
28378942
9.

Understanding the priorities for women diagnosed with lymphangioleiomyomatosis: a patient perspective.

Bassi I, Hollis G, Cottin V, Harari S, Zwanenburg E, Veltkamp M, Casanova A, Fletcher M, Masefield S, Powell P, Boyd J.

ERJ Open Res. 2016 Apr 21;2(2). pii: 00102-2015. eCollection 2016 Apr.

10.

Prehospital ketamine use by paramedics in the Australian Capital Territory: A 12 month retrospective analysis.

Hollis GJ, Keene TM, Ardlie RM, Caldicott DG, Stapleton SG.

Emerg Med Australas. 2017 Feb;29(1):89-95. doi: 10.1111/1742-6723.12685. Epub 2016 Oct 3.

PMID:
27699989
11.

Extrapolating human judgments from skip-gram vector representations of word meaning.

Hollis G, Westbury C, Lefsrud L.

Q J Exp Psychol (Hove). 2017 Aug;70(8):1603-1619. doi: 10.1080/17470218.2016.1195417. Epub 2016 Jun 24.

PMID:
27251936
12.

The principals of meaning: Extracting semantic dimensions from co-occurrence models of semantics.

Hollis G, Westbury C.

Psychon Bull Rev. 2016 Dec;23(6):1744-1756. Review.

PMID:
27138012
13.

Rhetoric and reality - matching palliative care services to meet the needs of patients of all ages, with any diagnosis.

Booth S, Fallon M, Hollis G.

Palliat Med. 2016 Jan;30(1):3-5. doi: 10.1177/0269216315619129. No abstract available.

PMID:
26667176
14.

The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy.

Zhang Q, Zhang Y, Diamond S, Boer J, Harris JJ, Li Y, Rupar M, Behshad E, Gardiner C, Collier P, Liu P, Burn T, Wynn R, Hollis G, Yeleswaram S.

Drug Metab Dispos. 2014 Oct;42(10):1656-62. doi: 10.1124/dmd.114.058883. Epub 2014 Jul 25.

15.

Integrating Nurse Practitioners Into Radiation Oncology: One Institution's Experience.

Hollis G, McMenamin E.

J Adv Pract Oncol. 2014 Jan;5(1):42-6. Review. No abstract available.

16.

Opportunities for multidisciplinary collaboration when caring for women with breast cancer.

Hollis G, Stricker CT.

J Obstet Gynecol Neonatal Nurs. 2014 May-Jun;43(3):359-60. doi: 10.1111/1552-6909.12299. Epub 2014 Apr 1. No abstract available.

PMID:
24690030
17.

Now you see it, now you don't: on emotion, context, and the algorithmic prediction of human imageability judgments.

Westbury CF, Shaoul C, Hollis G, Smithson L, Briesemeister BB, Hofmann MJ, Jacobs AM.

Front Psychol. 2013 Dec 26;4:991. doi: 10.3389/fpsyg.2013.00991. eCollection 2013.

18.

Connected text reading and differences in text reading fluency in adult readers.

Wallot S, Hollis G, van Rooij M.

PLoS One. 2013 Aug 20;8(8):e71914. doi: 10.1371/journal.pone.0071914. eCollection 2013.

19.

Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples.

Collier P, Patel K, Waeltz P, Rupar M, Luthra R, Liu PC, Hollis G, Huber R, Verstovsek S, Burn TC.

Genet Test Mol Biomarkers. 2013 May;17(5):429-37. doi: 10.1089/gtmb.2012.0366. Epub 2013 Mar 28.

20.

Out-of-pocket expenses and treatment choice for men with prostate cancer.

Jung OS, Guzzo T, Lee D, Mehler M, Christodouleas J, Deville C, Hollis G, Shah A, Vapiwala N, Wein A, Pauly M, Bekelman JE.

Urology. 2012 Dec;80(6):1252-7. doi: 10.1016/j.urology.2012.08.027. Epub 2012 Oct 23.

21.

The blue-collar brain.

Van Orden G, Hollis G, Wallot S.

Front Physiol. 2012 Jun 18;3:207. doi: 10.3389/fphys.2012.00207. eCollection 2012.

22.

Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist.

Xue CB, Wang A, Han Q, Zhang Y, Cao G, Feng H, Huang T, Zheng C, Xia M, Zhang K, Kong L, Glenn J, Anand R, Meloni D, Robinson DJ, Shao L, Storace L, Li M, Hughes RO, Devraj R, Morton PA, Rogier DJ, Covington M, Scherle P, Diamond S, Emm T, Yeleswaram S, Contel N, Vaddi K, Newton R, Hollis G, Metcalf B.

ACS Med Chem Lett. 2011 Oct 5;2(12):913-8. doi: 10.1021/ml200199c. eCollection 2011 Dec 8.

23.

A light-hearted look at patient overcrowding: the extended Emergency Department Cardiology Analogy Model (e-EDCAM).

Craven JA, Hollis G, Richardson DB.

Emerg Med Australas. 2011 Aug;23(4):512-3. doi: 10.1111/j.1742-6723.2011.01421.x. No abstract available.

PMID:
21824321
24.

Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.

Fridman JS, Scherle PA, Collins R, Burn T, Neilan CL, Hertel D, Contel N, Haley P, Thomas B, Shi J, Collier P, Rodgers JD, Shepard S, Metcalf B, Hollis G, Newton RC, Yeleswaram S, Friedman SM, Vaddi K.

J Invest Dermatol. 2011 Sep;131(9):1838-44. doi: 10.1038/jid.2011.140. Epub 2011 Jun 16.

25.

Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist.

Xue CB, Feng H, Cao G, Huang T, Glenn J, Anand R, Meloni D, Zhang K, Kong L, Wang A, Zhang Y, Zheng C, Xia M, Chen L, Tanaka H, Han Q, Robinson DJ, Modi D, Storace L, Shao L, Sharief V, Li M, Galya LG, Covington M, Scherle P, Diamond S, Emm T, Yeleswaram S, Contel N, Vaddi K, Newton R, Hollis G, Friedman S, Metcalf B.

ACS Med Chem Lett. 2011 Mar 31;2(6):450-4. doi: 10.1021/ml200030q. eCollection 2011 Jun 9.

26.

Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.

Shin N, Solomon K, Zhou N, Wang KH, Garlapati V, Thomas B, Li Y, Covington M, Baribaud F, Erickson-Viitanen S, Czerniak P, Contel N, Liu P, Burn T, Hollis G, Yeleswaram S, Vaddi K, Xue CB, Metcalf B, Friedman S, Scherle P, Newton R.

J Pharmacol Exp Ther. 2011 Jul;338(1):228-39. doi: 10.1124/jpet.111.179531. Epub 2011 Apr 1.

27.

Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist.

Zheng C, Cao G, Xia M, Feng H, Glenn J, Anand R, Zhang K, Huang T, Wang A, Kong L, Li M, Galya L, Hughes RO, Devraj R, Morton PA, Rogier DJ, Covington M, Baribaud F, Shin N, Scherle P, Diamond S, Yeleswaram S, Vaddi K, Newton R, Hollis G, Friedman S, Metcalf B, Xue CB.

Bioorg Med Chem Lett. 2011 Mar 1;21(5):1442-6. doi: 10.1016/j.bmcl.2011.01.015. Epub 2011 Jan 11.

PMID:
21295478
28.

Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 Activity.

Xue CB, Chen L, Cao G, Zhang K, Wang A, Meloni D, Glenn J, Anand R, Xia M, Kong L, Huang T, Feng H, Zheng C, Li M, Galya L, Zhou J, Shin N, Baribaud F, Solomon K, Scherle P, Zhao B, Diamond S, Emm T, Keller D, Contel N, Yeleswaram S, Vaddi K, Hollis G, Newton R, Friedman S, Metcalf B.

ACS Med Chem Lett. 2010 Aug 25;1(9):483-7. doi: 10.1021/ml1001536. eCollection 2010 Dec 9.

29.

11β-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus.

Hollis G, Huber R.

Diabetes Obes Metab. 2011 Jan;13(1):1-6. doi: 10.1111/j.1463-1326.2010.01305.x. Review.

PMID:
21114597
30.

Diagnosis and management of opioid-induced bowel dysfunction in patients with advanced cancer.

Fredericks A, Hollis G, Stricker CT.

Clin J Oncol Nurs. 2010 Dec;14(6):701-4. doi: 10.1188/10.CJON.701-704.

PMID:
21112848
31.

Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.

Xue CB, Wang A, Meloni D, Zhang K, Kong L, Feng H, Glenn J, Huang T, Zhang Y, Cao G, Anand R, Zheng C, Xia M, Han Q, Robinson DJ, Storace L, Shao L, Li M, Brodmerkel CM, Covington M, Scherle P, Diamond S, Yeleswaram S, Vaddi K, Newton R, Hollis G, Friedman S, Metcalf B.

Bioorg Med Chem Lett. 2010 Dec 15;20(24):7473-8. doi: 10.1016/j.bmcl.2010.10.020. Epub 2010 Oct 13.

PMID:
21036044
32.

Phosphorylation State-Dependent High Throughput Screening of the c-Met Kinase.

Behshad E, Klabe RM, Margulis A, Becker-Pasha M, Rupar MJ, Collier P, Liu PC, Hollis GF, Burn TC, Wynn R.

Curr Chem Genomics. 2010 Apr 23;4:27-33. doi: 10.2174/1875397301004010027.

33.

The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy.

Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, Hollis G, Flores R, Levy R, Williams WV, Seckl JR, Huber R; INCB13739-202 Principal Investigators.

Diabetes Care. 2010 Jul;33(7):1516-22. doi: 10.2337/dc09-2315. Epub 2010 Apr 22.

34.

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.

Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF, Wen X, Shi J, McGee R, Haley PJ, Shepard S, Rodgers JD, Yeleswaram S, Hollis G, Newton RC, Metcalf B, Friedman SM, Vaddi K.

J Immunol. 2010 May 1;184(9):5298-307. doi: 10.4049/jimmunol.0902819. Epub 2010 Apr 2.

35.

Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.

Liu PC, Caulder E, Li J, Waeltz P, Margulis A, Wynn R, Becker-Pasha M, Li Y, Crowgey E, Hollis G, Haley P, Sparks RB, Combs AP, Rodgers JD, Burn TC, Vaddi K, Fridman JS.

Clin Cancer Res. 2009 Nov 15;15(22):6891-900. doi: 10.1158/1078-0432.CCR-09-1298. Epub 2009 Nov 3.

36.

Fostering health equity: clinical and research training strategies from nursing education.

Deatrick JA, Lipman TH, Gennaro S, Sommers M, de Leon Siantz ML, Mooney-Doyle K, Hollis G, Jemmott LS.

Kaohsiung J Med Sci. 2009 Sep;25(9):479-85. doi: 10.1016/S1607-551X(09)70554-6.

37.

Isolation of polymorphic tri- and tetranucleotide microsatellite loci for the highly endangered Baw Baw frog (Philoria frosti).

Wheaton L, Donnellan SC, Gardner MG, Hollis GJ.

Mol Ecol Resour. 2008 May;8(3):593-5. doi: 10.1111/j.1471-8286.2007.02006.x.

PMID:
21585842
38.

Frequency of the HAL-1843 mutation of the ryanodine receptor gene in dead and nonambulatory-noninjured pigs on arrival at the packing plant.

Ritter MJ, Ellis M, Hollis GR, McKeith FK, Orellana DG, Van Genugten P, Curtis SE, Schlipf JM.

J Anim Sci. 2008 Mar;86(3):511-4. Epub 2007 Dec 11.

PMID:
18073280
39.

Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.

Burns DM, He C, Li Y, Scherle P, Liu X, Marando CA, Covington MB, Yang G, Pan M, Turner S, Fridman JS, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B, Yao W.

Bioorg Med Chem Lett. 2008 Jan 15;18(2):560-4. Epub 2007 Nov 28.

PMID:
18068976
40.

Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.

Yao W, Zhuo J, Burns DM, Li YL, Qian DQ, Zhang C, He C, Xu M, Shi E, Li Y, Marando CA, Covington MB, Yang G, Liu X, Pan M, Fridman JS, Scherle P, Wasserman ZR, Hollis G, Vaddi K, Yeleswaram S, Newton R, Friedman S, Metcalf B.

Bioorg Med Chem Lett. 2008 Jan 1;18(1):159-63. Epub 2007 Nov 4.

PMID:
18036818
41.

High-throughput determination of mode of inhibition in lead identification and optimization.

Wei M, Wynn R, Hollis G, Liao B, Margulis A, Reid BG, Klabe R, Liu PC, Becker-Pasha M, Rupar M, Burn TC, McCall DE, Li Y.

J Biomol Screen. 2007 Mar;12(2):220-8.

PMID:
17351185
42.

Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.

Yao W, Zhuo J, Burns DM, Xu M, Zhang C, Li YL, Qian DQ, He C, Weng L, Shi E, Lin Q, Agrios C, Burn TC, Caulder E, Covington MB, Fridman JS, Friedman S, Katiyar K, Hollis G, Li Y, Liu C, Liu X, Marando CA, Newton R, Pan M, Scherle P, Taylor N, Vaddi K, Wasserman ZR, Wynn R, Yeleswaram S, Jalluri R, Bower M, Zhou BB, Metcalf B.

J Med Chem. 2007 Feb 22;50(4):603-6. Epub 2007 Jan 26.

PMID:
17256836
43.

Structural insights into the design of nonpeptidic isothiazolidinone-containing inhibitors of protein-tyrosine phosphatase 1B.

Ala PJ, Gonneville L, Hillman M, Becker-Pasha M, Yue EW, Douty B, Wayland B, Polam P, Crawley ML, McLaughlin E, Sparks RB, Glass B, Takvorian A, Combs AP, Burn TC, Hollis GF, Wynn R.

J Biol Chem. 2006 Dec 8;281(49):38013-21. Epub 2006 Oct 6.

44.

NUANCE 3.0: using genetic programming to model variable relationships.

Hollis G, Westbury CE, Peterson JB.

Behav Res Methods. 2006 May;38(2):218-28.

PMID:
16956097
45.

Structural basis for inhibition of protein-tyrosine phosphatase 1B by isothiazolidinone heterocyclic phosphonate mimetics.

Ala PJ, Gonneville L, Hillman MC, Becker-Pasha M, Wei M, Reid BG, Klabe R, Yue EW, Wayland B, Douty B, Polam P, Wasserman Z, Bower M, Combs AP, Burn TC, Hollis GF, Wynn R.

J Biol Chem. 2006 Oct 27;281(43):32784-95. Epub 2006 Aug 17.

46.

NUANCE: Naturalistic University of Alberta Nonlinear Correlation Explorer.

Hollis G, Westbury C.

Behav Res Methods. 2006 Feb;38(1):8-23.

PMID:
16817509
47.

Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic.

Combs AP, Zhu W, Crawley ML, Glass B, Polam P, Sparks RB, Modi D, Takvorian A, McLaughlin E, Yue EW, Wasserman Z, Bower M, Wei M, Rupar M, Ala PJ, Reid BM, Ellis D, Gonneville L, Emm T, Taylor N, Yeleswaram S, Li Y, Wynn R, Burn TC, Hollis G, Liu PC, Metcalf B.

J Med Chem. 2006 Jun 29;49(13):3774-89.

PMID:
16789735
48.

Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells.

Liu PC, Liu X, Li Y, Covington M, Wynn R, Huber R, Hillman M, Yang G, Ellis D, Marando C, Katiyar K, Bradley J, Abremski K, Stow M, Rupar M, Zhuo J, Li YL, Lin Q, Burns D, Xu M, Zhang C, Qian DQ, He C, Sharief V, Weng L, Agrios C, Shi E, Metcalf B, Newton R, Friedman S, Yao W, Scherle P, Hollis G, Burn TC.

Cancer Biol Ther. 2006 Jun;5(6):657-64. Epub 2006 Jun 14.

PMID:
16627989
49.

Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics.

Combs AP, Yue EW, Bower M, Ala PJ, Wayland B, Douty B, Takvorian A, Polam P, Wasserman Z, Zhu W, Crawley ML, Pruitt J, Sparks R, Glass B, Modi D, McLaughlin E, Bostrom L, Li M, Galya L, Blom K, Hillman M, Gonneville L, Reid BG, Wei M, Becker-Pasha M, Klabe R, Huber R, Li Y, Hollis G, Burn TC, Wynn R, Liu P, Metcalf B.

J Med Chem. 2005 Oct 20;48(21):6544-8.

PMID:
16220970
50.

Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344.

Brodmerkel CM, Huber R, Covington M, Diamond S, Hall L, Collins R, Leffet L, Gallagher K, Feldman P, Collier P, Stow M, Gu X, Baribaud F, Shin N, Thomas B, Burn T, Hollis G, Yeleswaram S, Solomon K, Friedman S, Wang A, Xue CB, Newton RC, Scherle P, Vaddi K.

J Immunol. 2005 Oct 15;175(8):5370-8.

Supplemental Content

Loading ...
Support Center